Medication topics
Sulfasalazine articles covering 5-ASA treatment, safety, access, and ulcerative colitis or broader IBD care decisions. Medication context emphasizes treatment decisions, safety, approvals, and therapy access.
8 articles
The study presents a preclinical strategy to concentrate an existing antihistamine drug in the colon and reduce systemic exposure, which could improve local efficacy and safety for IBD treatment if later validated in...
The report highlights a serious drug-related complication (pancytopenia/myelosuppression and hair loss) in a patient treated with azathioprine plus sulfasalazine for ulcerative colitis, suggesting clinicians and patients...
This label update confirms current FDA prescribing information for sulfasalazine delayed‑release tablets, which many people with ulcerative colitis may be prescribed for induction and maintenance of remission.
This DailyMed entry is an official FDA drug-label record describing indications, dosing, and safety information for sulfasalazine—an older prescription medication still used in ulcerative colitis. Updated label details...
Extrapulmonary TB can be triggered or revealed during immunosuppressive biologic therapy and may mimic other causes of liver injury; early recognition and TB-specific testing are important for timely treatment and to...
The work targets oxidative/nitrosative stress and mucosal repair—mechanisms important in IBD—using a novel delivery vehicle that pairs an approved anti-inflammatory drug with catalytic cerium ions. If translated, this...
Market reports can signal which drugs, companies, and biosimilars are becoming more available and may affect access and cost. Announcements about biosimilars could influence treatment affordability and prescribing...
You can have active intestinal inflammation even without clear symptoms; early monitoring and tailored treatment aim to prevent complications and preserve quality of life.
